Roche Diagnostics Steps Up Services, Eyes Laboratory Tie-up
This article was originally published in PharmAsia News
Executive Summary
Roche Diagnostics recently disclosed that it will step up efforts to get a slice of China's RMB 850 billion healthcare reform pie. Although the company's product portfolio includes devices catering to China's small- and mid-sized hospitals and rural specialists, it enjoys no price advantage. To address this, the firm will compete by providing high-level services. In addition, Roche Diagnostics will collaborate with local independent laboratories to meet the outsourced testing needs of small hospitals that do not own clinical testing departments. The company does not discount the possibility of acquisitions or partnerships to enhance its R&D in China. (Click here for more - Chinese Language)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.